{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T01:18:32Z","timestamp":1783559912468,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jtocrr.2025.100844","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T12:00:07Z","timestamp":1747310407000},"page":"100844","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of the Safety, Pharmacokinetics, and Antitumor Activity of Tusamitamab Ravtansine in Patients With Nonsquamous NSCLC With High or Moderate Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5"],"prefix":"10.1016","volume":"6","author":[{"given":"Anas","family":"Gazzah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Ricordel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Italiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byoung Chul","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliano","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Wan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Helissey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Vieito","family":"Villar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Ghiringhelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Cousin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Paz-Ares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Fagniez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustapha","family":"Chadjaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Bauchet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Soufflet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Masson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Barlesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2025.100844_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jtocrr.2025.100844_bib2","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jtocrr.2025.100844_bib3","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jtocrr.2025.100844_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178420","article-title":"Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting","volume":"12","author":"Abernethy","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jtocrr.2025.100844_bib5","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.cllc.2018.02.002","article-title":"Treatment patterns and clinical outcomes among metastatic non-small-cell lung cancer patients treated in the community practice setting","volume":"19","author":"Nadler","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtocrr.2025.100844_bib6","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.2217\/fon-2019-0348","article-title":"Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting","volume":"15","author":"Simeone","year":"2019","journal-title":"Future Oncol"},{"key":"10.1016\/j.jtocrr.2025.100844_bib7","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.lungcan.2021.12.002","article-title":"Antibody-drug conjugates: a promising novel therapeutic approach in lung cancer","volume":"163","author":"Desai","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtocrr.2025.100844_bib8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1006\/scbi.1998.0119","article-title":"The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues","volume":"9","author":"Hammarstr\u00f6m","year":"1999","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.jtocrr.2025.100844_bib9","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1158\/1078-0432.CCR-19-4051","article-title":"Preclinical activity of SAR408701: a novel anti-CEACAM5-maytansinoid antibody-drug conjugate for the treatment of CEACAM5-positive epithelial tumors","volume":"26","author":"Decary","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2025.100844_bib10","article-title":"CEACAM5 stimulates the progression of non-small-cell lung cancer by promoting cell proliferation and migration","volume":"48","author":"Zhang","year":"2020","journal-title":"J Int Med Res"},{"key":"10.1016\/j.jtocrr.2025.100844_bib11","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1021\/acs.jproteome.5b00819","article-title":"Quantitative secretomic analysis identifies extracellular protein factors that modulate the metastatic phenotype of non-small cell lung cancer","volume":"15","author":"Hu","year":"2016","journal-title":"J Proteome Res"},{"key":"10.1016\/j.jtocrr.2025.100844_bib12","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3390\/ijms22020925","article-title":"Assessment of the efficacy and clinical utility of different circulating tumor cell (CTC) detection assays in patients with chemotherapy-naive advanced or metastatic non-small cell lung cancer (NSCLC)","volume":"22","author":"Papadaki","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtocrr.2025.100844_bib13","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1038\/s41467-023-37979-8","article-title":"The blood proteome of imminent lung cancer diagnosis","volume":"14","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtocrr.2025.100844_bib14","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10928-021-09799-0","article-title":"Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate","volume":"49","author":"Pouzin","year":"2022","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.jtocrr.2025.100844_bib15","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1126\/science.1241159","article-title":"Antimitotic activity of the potent tumor inhibitor maytansine","volume":"189","author":"Remillard","year":"1975","journal-title":"Science"},{"key":"10.1016\/j.jtocrr.2025.100844_bib16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1021\/bc900315y","article-title":"Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates","volume":"21","author":"Erickson","year":"2010","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.jtocrr.2025.100844_bib17","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.annonc.2021.12.012","article-title":"Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study","volume":"33","author":"Gazzah","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2025.100844_bib18","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1158\/2767-9764.CRC-23-0284","article-title":"Tusamitamab ravtansine in patients with advanced solid tumors: phase I study of safety, pharmacokinetics, and antitumor activity using alternative dosing regimens","volume":"3","author":"Tabernero","year":"2023","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.jtocrr.2025.100844_bib19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtocrr.2025.100844_bib20","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1158\/1078-0432.CCR-13-2098","article-title":"Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials","volume":"20","author":"Fert\u00e9","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2025.100844_bib21","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/psp4.12769","article-title":"Covariate analysis of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate, based on first-in-human study","volume":"11","author":"Pouzin","year":"2022","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.jtocrr.2025.100844_bib22","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.e15003","article-title":"Phase 1\/2 study of tusamitamab ravtansine in patients with advanced solid tumors: pooled safety analysis of corneal adverse events","volume":"41","author":"Gazzah","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.jtocrr.2025.100844_bib24","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","article-title":"Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates","volume":"8","author":"Donaghy","year":"2016","journal-title":"mAbs"},{"key":"10.1016\/j.jtocrr.2025.100844_bib25","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","article-title":"Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates","volume":"200","author":"Mahalingaiah","year":"2019","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jtocrr.2025.100844_bib26","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/0008-5472.CAN-17-3202","article-title":"Modulation of macropinocytosis-mediated internalization decreases ocular toxicity of antibody-drug conjugates","volume":"78","author":"Zhao","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtocrr.2025.100844_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107356","article-title":"The search for therapeutic targets in lung cancer: preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 expression and its associated molecular landscape","volume":"184","author":"Lefebvre","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtocrr.2025.100844_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2018.04.003","article-title":"\u201cNo pain, no gain\u201d still true with immunotherapy: when the finger shows the moon, look at the moon","volume":"127","author":"Milano","year":"2018","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266636432500061X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266636432500061X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T22:13:34Z","timestamp":1760739214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266636432500061X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S266636432500061X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2025.100844","relation":{},"ISSN":["2666-3643"],"issn-type":[{"value":"2666-3643","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the Safety, Pharmacokinetics, and Antitumor Activity of Tusamitamab Ravtansine in Patients With Nonsquamous NSCLC With High or Moderate Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2025.100844","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the International Association for the Study of Lung Cancer\u00e9","name":"copyright","label":"Copyright"}],"article-number":"100844"}}